title: Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: An international update.
abstract: Based on the results of two recent trials, docetaxel (Taxotere; Aventis, Antony, France) is now the drug of choice for the treatment of advanced non-small cell lung cancer that is refractory to primary chemotherapy. Trials are testing the role of docetaxel in the induction setting, as well as concomitantly with radiation therapy.
authors.affiliation: From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY U.S.A.; From the Thorax Klinik, Heidelberg, Germany.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Kris
authors.affiliation: From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY U.S.A.; From the Thorax Klinik, Heidelberg, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Manegold